Media Articles Related to Nucynta (Tapentadol)
High-Risk Plaque Predicts ACS in ER Patients With Chest Pain
Source: theheart.org | Medscape Cardiology Headlines [2014.07.18]
Among patients with acute chest pain but a negative initial assessment in the ER, a coronary CT scan that detects plaque with certain features such as napkin-ring sign may identify imminent MI.
Exercises With or Without Abdominal Bracing in Back Pain
Source: Medscape Orthopaedics Headlines [2014.07.17]
Which type of exercise is more important in patients with recurrent low back pain -- and how does abdominal bracing influence the exercise effect?
Could 'Phone Care' Ring in New Approach to Pain Relief?
Source: MedicineNet Chronic Pain Specialty [2014.07.16]
Title: Could 'Phone Care' Ring in New Approach to Pain Relief?
Category: Health News
Created: 7/15/2014 4:35:00 PM
Last Editorial Review: 7/16/2014 12:00:00 AM
Weather May Not Affect Low Back Pain
Source: Medscape Rheumatology Headlines [2014.07.15]
Weather factors such as temperature, relative humidity, air pressure, and precipitation did not increase the risk for a low back pain episode; higher wind and wind gust speed had a minimal effect.
Medscape Medical News
Telecare intervention improves chronic pain
Source: Pain / Anesthetics News From Medical News Today [2014.07.15]
A telephone-delivered intervention, which included automated symptom monitoring, produced clinically meaningful improvements in chronic musculoskeletal pain compared to usual care, according to a...
Published Studies Related to Nucynta (Tapentadol)
Effect of tapentadol extended release on productivity: results from an analysis
combining evidence from multiple sources. 
OBJECTIVE: To compare the effects of tapentadol-extended release versus
oxycodone-controlled release for pain relief on productivity by combining
evidence from different sources.
Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. [2011.05]
INTRODUCTION: Two randomized, double-blind, placebo-controlled studies in acute and chronic pain treatment, powered to assess noninferiority of the efficacy of tapentadol immediate release (IR) (50 mg, 75 mg) versus oxycodone hydrochloride (HCl) IR (10 mg), established comparable efficacy of tapentadol IR with oxycodone HCl IR, and suggested tapentadol IR's improved gastrointestinal tolerability. The impact of these equianalgesic doses of tapentadol and oxycodone HCl on bowel function and gastrointestinal tolerability was then directly assessed in the current study, using a validated bowel function diary to comprehensively assess opioid-induced constipation symptoms and outcomes... CONCLUSION: Tapentadol IR (50 mg, 75 mg) consistently demonstrated superior gastrointestinal tolerability, including for the most commonly reported events, such as nausea, vomiting, and constipation at doses that provide comparable efficacy with oxycodone HCl IR 10 mg. These findings validate and extend the tolerability findings of the two earlier studies that established comparable efficacy of these tapentadol and oxycodone HCl doses.
Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. [2011.01]
CONCLUSIONS: Compared with placebo, tapentadol ER 100-250 mg bid provided a statistically significant difference in the maintenance of a clinically important improvement in pain 1 , 2 and was well-tolerated by patients with painful DPN.
Post hoc analyses of data from a 90-day clinical trial evaluating the
tolerability and efficacy of tapentadol immediate release and oxycodone immediate
release for the relief of moderate to severe pain in elderly and nonelderly
and nonelderly patients... CONCLUSIONS: Tapentadol IR was safe and effective for the relief of lower back
Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. [2010.12.02]
Abstract Objective: Painful diabetic peripheral neuropathy (DPN) may not be adequately managed with available therapeutic options. This phase III, randomized-withdrawal, placebo-controlled trial evaluated the safety and efficacy of tapentadol extended release (ER) for relieving painful DPN... Conclusions: Compared with placebo, tapentadol ER 100-250 mg bid provided a statistically significant difference in the maintenance of a clinically important improvement in pain 1 , 2 and was well-tolerated by patients with painful DPN.
Clinical Trials Related to Nucynta (Tapentadol)
Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin [Recruiting]
The main objective of the study is to evaluate the effectiveness, safety, and tolerability
of increasing doses of tapentadol prolonged release (PR) (500 mg per day) versus a
combination of tapentadol PR (300 mg per day) and pregabalin (to 300 mg per day) in subjects
requiring additional analgesia after titration to tapentadol PR 300 mg per day.
This is a clinical effectiveness trial designed to establish a link between anticipated
clinical outcomes and the clinical practice by means of selected measures of clinical and
subject reported outcomes. Since, severe low back pain with a neuropathic component, the
targeted study population, is frequently treated with a combination therapy (monotherapy is
often not effective enough) it is of interest to determine if tapentadol alone (combining 2
mechanisms of action in a single molecule) could be as effective as a combination of
tapentadol plus pregabalin. Furthermore, the tolerability profiles of monotherapy versus
combination are of interest.
NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain [Recruiting]
Evaluate how NUCYNTA (tapentadol) immediate release (IR) compares with oxycodone IR in the
treatment of acute low back pain.
A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy [Recruiting]
The purpose of this study is to demonstrate the efficacy of at least 1 dose of tapentadol IR
50 mg and/or 75 mg versus placebo using the sum of pain intensity difference at 48 hours
(SPID48) to measure analgesic effect in Korean patients with acute pain following
A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain [Not yet recruiting]
A Safety and Effectiveness Study of Immediate Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Acute Non-Cancer Pain [Not yet recruiting]
Reports of Suspected Nucynta (Tapentadol) Side Effects
Drug Ineffective (20),
Confusional State (17),
Feeling Abnormal (17),
Withdrawal Syndrome (16),
Anxiety (14), more >>